Search

Displaying results 2671 - 2680 of 10000 in total
  1. Target

    Transient receptor potential cation channel subfamily V member 3

    go.drugbank.com/bio_entities/BE0003416
    TargetHumans

    Non-selective calcium permeant cation channel (PubMed:12077604, PubMed:12077606, PubMed:26818531, PubMed:37648856, PubMed:38691614). It is activated by innocuous (warm) temperatures and shows an increased response at noxious temperatures...

    Polypeptides: Transient receptor potential cation channel subfamily V member 3Synonyms: Vanilloid receptor-like 3
  2. Target

    Transient receptor potential cation channel subfamily M member 7

    go.drugbank.com/bio_entities/BE0004624
    TargetTransporterHumans

    Bifunctional protein that combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular functions either by conducting ions through the pore or by phosphorylating downstream proteins via its kinase domain. The...

    Polypeptides: Transient receptor potential cation channel subfamily M member 7Synonyms: Long transient receptor potential channel 7
  3. Target

    Transient receptor potential cation channel subfamily V member 5

    go.drugbank.com/bio_entities/BE0005112
    TransporterHumans

    Constitutively active calcium selective cation channel thought to be involved in Ca(2+) reabsorption in kidney and intestine (PubMed:11549322, PubMed:18768590). Required for normal Ca(2+) reabsorption in the kidney distal convoluted tubu...

    Polypeptides: Transient receptor potential cation channel subfamily V member 5
  4. Target

    Transient receptor potential cation channel subfamily M member 6

    go.drugbank.com/bio_entities/BE0005126
    TransporterHumans

    Bifunctional protein that combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular functions either by conducting ions through the pore or by phosphorylating downstream proteins via its kinase domain (Pub...

    Polypeptides: Transient receptor potential cation channel subfamily M member 6
  5. Target

    Transient receptor potential cation channel subfamily V member 4

    go.drugbank.com/bio_entities/BE0009159
    TargetHumans

    Non-selective calcium permeant cation channel involved in osmotic sensitivity and mechanosensitivity (PubMed:16293632, PubMed:18695040, PubMed:18826956, PubMed:22526352, PubMed:23136043, PubMed:29899501). Activation by exposure to hypoto...

    Polypeptides: Transient receptor potential cation channel subfamily V member 4Synonyms: Vanilloid receptor-like channel 2, Vanilloid receptor-like protein 2
  6. Target

    B-cell antigen receptor complex-associated protein beta chain

    go.drugbank.com/bio_entities/BE0009680
    TargetHumans

    Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to

    Polypeptides: B-cell antigen receptor complex-associated protein beta chain
  7. Target

    Transient receptor potential cation channel subfamily M member 4

    go.drugbank.com/bio_entities/BE0009748
    TargetHumans

    Enhances cell proliferation through up-regulation of the beta-catenin signaling pathway. Plays a role in keratinocyte differentiation (PubMed:30528822)

    Polypeptides: Transient receptor potential cation channel subfamily M member 4Synonyms: Long transient receptor potential channel 4
  8. Drug

    LX-7101

    go.drugbank.com/drugs/DB16009
    Investigational

    LX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).

  9. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    Hemophilia B - also called factor IX deficiency or Christmas disease - is an X-linked genetic disorder resulting in an absence or deficiency of clotting factor IX. … [L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity.

  10. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna.